The Technical Analyst
GB Sciences, Inc. [GBLX]
Exchange: PNK Industry: Biotechnology
GB Sciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.41% $0.0065
America/New_York / 3 mai 2024 @ 15:37
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.64 mill |
| EPS: | -0.0100 |
| P/E: | -0.650 |
| Earnings Date: | Jul 12, 2024 |
| SharesOutstanding: | 406.07 mill |
| Avg Daily Volume: | 0.123 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.650 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.650 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0036 (-155.31%) $-0.0101 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0055 - 0.0075 ( +/- 15.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2018-07-11 | Poss John C | Buy | 3 615 | Common Stock |
| 2018-07-11 | Poss John C | Buy | 11 915 | Common Stock |
| 2018-07-11 | Poss John C | Buy | 20 000 | Common Stock |
| 2018-07-11 | Poss John C | Buy | 1 250 | Common Stock |
| 2018-07-11 | Poss John C | Buy | 30 000 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 84 transactions |
| Buy: 3 790 243 | Sell: 13 501 701 |
Forecast:
16:00 - $0.0065
Live Trading Signals (every 1 min)
Forecast
1: 15:47 - $0.0060
Forecast 2: 16:00 - $0.0065
Forecast 3: 16:00 - $0.0065
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0065 (-4.41% ) |
| Volume | 0.0123 mill |
| Avg. Vol. | 0.123 mill |
| % of Avg. Vol | 10.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GBLX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GBLX
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Latest Press Releases
2021-09-14 07:00:00 - Press Release
Gb Sciences Achieves Positive Proof-of-concept Results For Their Cytokine Release Syndrome Therapies Designed To Suppress Covid-related Hyperinflammation
Based on a recently completed preclinical study performed at michigan state university, gb sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with covid-19 and other life-threatening inflammatory conditions. based on a recently completed preclinical study performed at michigan state university, gb sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with covid-19 and other life-threatening inflammatory conditions.
2021-09-09 09:54:00 - Press Release
Gb Sciences Presenting Covid-related Cytokine Release Syndrome Results At H.c. Wainwright's 23rd Annual Global Investment Conference
Highlighting gb sciences' development of plant-inspired therapies for covid-related cytokine release syndrome, chronic pain, and parkinson's disease during the healthcare & biotech track starting monday, september 13. highlighting gb sciences' development of plant-inspired therapies for covid-related cytokine release syndrome, chronic pain, and parkinson's disease during the healthcare & biotech track starting monday, september 13.
2021-07-27 10:10:00 - Press Release
Gb Sciences Is Developing Plant-inspired Mixtures For Anxiety, Depression, And Pain From Pharos, Gb Sciences' Proprietary Ai-accelerated Drug Discovery Platform
Gb sciences used pharos™, their novel ai-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtures of compounds identified within kava and other plants from within the piper family. las vegas, nv / accesswire / july 27, 2021 / gb sciences, inc. (otcqb:gblx) announced the completion of a data science study identifying proprietary therapeutic mixtures from within the piper plant family.
2021-06-29 07:00:00 - Press Release
Gb Sciences Using Ai Technology In Plant-based Drug Discovery Research
Biotech innovator gb sciences has launched a drug discovery platform using ai technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. las vegas, nv / accesswire / june 29, 2021 / gb sciences (otcqb:gblx) is leading the way in cutting-edge biopharmaceutical research with its novel ai-accelerated drug discovery platform-pharos™ - phytomedical analytics for research optimization at scale.
2021-06-17 11:20:00 - Press Release
Gb Sciences' Board Of Directors Has Passed A Unanimous Written Consent Promoting Dr. Andrea Small-howard To The Role Of President
The uwc also retains john poss as chairman and ceo of gb sciences, inc. las vegas, nv / accesswire / june 17, 2021 / dr. andrea small-howard has been promoted to the role of president of gb sciences, inc. dr. small-howard will also retain her roles as chief science officer and member of the board of directors. andrea small howard joining gb sciences in june of 2014 as the chief science officer and a founding member of the board of directors, dr. small-howard has made considerable contributions to the strategic vision and forward trajectory of the company.
Latest News
2021-09-14 07:00:00 - GlobeNewsWire
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions. Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.
2021-09-09 09:54:00 - GlobeNewsWire
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13. Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.
2021-07-27 10:10:00 - Accesswire
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtures of compounds identified within Kava and other plants from within the Piper family. LAS VEGAS, NV / ACCESSWIRE / July 27, 2021 / GB Sciences, Inc. (OTCQB:GBLX) announced the completion of a data science study identifying proprietary therapeutic mixtures from within the Piper plant family.
2021-06-29 07:00:00 - Accesswire
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. LAS VEGAS, NV / ACCESSWIRE / June 29, 2021 / GB Sciences (OTCQB:GBLX) is leading the way in cutting-edge biopharmaceutical research with its novel AI-accelerated drug discovery platform-PhAROS™ - Phytomedical Analytics for Research Optimization at Scale.
2021-06-17 11:20:00 - Accesswire
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc. LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 / Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, Inc. Dr. Small-Howard will also retain her roles as Chief Science Officer and member of the board of directors. Andrea Small Howard Joining GB Sciences in June of 2014 as the Chief Science Officer and a founding member of the board of directors, Dr. Small-Howard has made considerable contributions to the strategic vision and forward trajectory of the Company.
2021-04-20 07:00:00 - Accesswire
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc. (OTCQB:GBLX) and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, today announced that GB Sciences has selected Purisys as their preferred vendor for the active pharmaceutical ingredients ("APIs") used in formulating GB Sciences' proprietary, cannabinoid-containing, optimized therapeutic mixtures (OTM).
2021-04-07 07:00:00 - Accesswire
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market.